EGFR and non-small cell lung carcinoma: A meta-analysis evaluating the safety and efficacy of concurrent TKI therapy with SRS or whole brain radiation therapy for brain metastases in the setting of Stage IV EGFR-mutated NSCLC reported a favorable toxicity profile and improved disease control rate [67].